-We sought to determine whether oxidative stress or a relative deficit of L-arginine plays a role in reducing cutaneous vasodilation in response to local heating in chronic kidney disease (CKD). Eight patients with stage 3-4 CKD and eight age-and sex-matched healthy control (HC) subjects were instrumented with four microdialysis (MD) fibers for the local delivery of 1) Ringers solution (R), 2) 20 mM ascorbic acid (AA), 3) 10 mM L-arginine (L-Arg), and 4) 10 mM N G -nitro-L-arginine methyl ester (L-NAME). Red blood cell (RBC) flux was measured via laser Doppler flowmetry. A standardized nonpainful local heating protocol (42°C) was used. Cutaneous vascular conductance (CVC) was calculated as RBC flux/MAP and all data were expressed as a percentage of the maximum CVC at each site (28 mM sodium nitroprusside, T loc ϭ 43°C). The plateau %CVC max was attenuated in CKD (CKD: 76 Ϯ 4 vs. HC: 91 Ϯ 2%CVC max; P Ͻ 0.05) and the NO contribution to the plateau was lower in CKD (CKD: 39 Ϯ 7, HC: 54 Ϯ 5; P Ͻ 0.05). The plateau %CVC max in the CKD group was significantly greater at the AA and L-Arg sites compared with R (AA: 89 Ϯ 2; L-Arg: 90 Ϯ 1; R: 76 Ϯ 4; P Ͻ 0.05) and did not differ from HC. Initial peak %CVC max was also significantly attenuated at the R and L-Arg sites in CKD (P Ͻ 0.05) but did not differ at the AA site. These results suggest that cutaneous microvascular function is impaired in stage 3-4 CKD and that oxidative stress and a deficit of L-arginine play a role in this impairment. skin blood flow; nitric oxide; oxidative stress CARDIOVASCULAR DISEASE (CVD) is the major cause of death among chronic kidney disease (CKD) patients (28, 41). Individuals with CKD are at risk of progressing toward end stage renal disease; however, they are more likely to die of CVD before reaching end stage renal disease (38, 39) . CKD is a progressive disease in which the risk for CVD is elevated early in the progression of CKD (38); therefore, it is important to understand the underlying mechanisms to develop interventions to slow the progression of CKD and reduce the risk of CVD.
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Endothelial dysfunction, characterized by a decreased bioavailability and/or production of nitric oxide, is present in CKD and has been suggested to contribute to the development of CVD as well as the progression of renal disease (34, 40) . The decreased availability of nitric oxide in CKD may be due to increased oxidative stress as well as an increase in asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS (49) .
Markers of oxidative stress are elevated in CKD (29, 33, 35) . Acute intra-arterial administration of vitamin C increased endothelial-dependent dilation in the resistance vasculature of predialysis and hemodialysis renal failure patients (8) , suggesting oxidative stress may play a role in vascular dysfunction observed in CKD. However, the role of oxidative stress in vascular dysfunction has yet to be investigated in earlier stages of CKD.
Oxidative stress and uremic toxins may increase the activity of protein arginine N-methyltransferases (PRMTs) and decrease the activity of dimethylarginine dimethylaminohydrolase (DDAH), which are redox-sensitive enzymes involved in the synthesis and degradation of ADMA, respectively (25, 48) . Increases in production of reactive oxygen species can lead to an increase in PRMT activity and a decrease in DDAH activity, causing formation of more ADMA as well as a decrease in ADMA degradation (46) . This results in increased NOS inhibition through the competition of ADMA with L-arginine for endothelial NOS. Hence, a deficit of L-arginine relative to increased ADMA levels may potentially be a mechanism contributing to the decreased bioavailability of nitric oxide in CKD.
The cutaneous circulation is an accessible vascular bed for the assessment of in vivo human microcirculatory function and may be representative of systemic vascular function (1, 16, 36, 43) . Furthermore, alterations in microvascular function may occur early in the progression of cardiovascular diseases (7, 16, 27) . Therefore we sought to determine whether oxidative stress and a relative deficit of L-arginine play a mechanistic role in reducing nitric oxide-mediated cutaneous vasodilation in response to local heating in patients with moderate to severe CKD. We hypothesized that nitric oxide-mediated cutaneous vasodilation in response to local heating would be lower in CKD patients compared with healthy control subjects but would be improved by the intradermal microdialysis of ascorbic acid or L-arginine.
METHODS
Subjects. Eight individuals (5 men, 3 women) with stages 3-4 CKD and eight age-and sex-matched apparently healthy individuals were studied. Stages 3 and 4 CKD is defined as an estimated glomerular filtration rate (eGFR) of Ͻ60 and Ͼ15 ml·min·1.73 m
Ϫ2
and was estimated using the Modification of Diet in Renal Disease equation based on serum creatinine, age, sex, and race (26) . Subjects with a history of myocardial infarction, angina, heart failure, hepatic disease, or current tobacco use were excluded from study participation. CKD patients were on a variety of antihypertensive medications, statins, insulin, and erythropoiesis-stimulating agents. Patients continued use of medications during study participation; however, they were instructed to delay taking medications other than those for treatment of diabetes on screening and testing days until after all testing had been completed. All healthy participants were required to have an eGFR of Ͼ60 as well as being free from disease as assessed by medical history and screening visit results.
Premenopausal women were studied during the early follicular phase of the menstrual cycle to control for any effects of the menstrual cycle on vascular function (19, 47) . The study was approved by the University of Delaware Institutional Review Board and all subjects gave oral and written informed consent prior to participation.
Screening visit. Subjects arrived at the laboratory after an overnight fast. Blood and urine samples were collected and sent to the local clinical laboratory to assess liver enzymes, blood lipid profiles, renal function, hemoglobin, hematocrit, glucose, and urinary albumin-to-creatinine ratio. Medical history and demographics were also collected.
Testing visit. Subjects arrived at the laboratory and were instrumented with four microdialysis fibers (MD 2000, Bioanalytical Systems; 10-mm, 30-kDa cutoff membrane) in the ventral side of the nondominant forearm. A 25-gauge needle was inserted through the dermis after a 10-min application of ice to the skin surface to achieve short-term local anesthesia. The entry and exit points of each needle were ϳ2.5 cm apart. The MD fibers were threaded through the lumen of the needle, which was removed once the semi-permeable membrane of the fiber was completely in the dermis. The fibers were then taped down, and subjects rested for 60 -90 min for the local hyperemia associated with fiber insertion to subside before beginning the protocol.
Skin blood flow was measured as cutaneous red blood cell (RBC) flux from 1.5 mm 2 of skin with a multi-fiber laser Doppler probe placed in a local heater (MoorLAB, Temperature Monitor SH02, Moor Instruments, Devon, UK). Each heater was placed directly on the skin above each MD site. Blood pressure was measured every 10 min on the contralateral arm by an automated oscillometric sphygmomanometer (Dinamap Dash 2000, GE medical Systems).
Experimental protocol. A standardized nonpainful local heating protocol was used (21, 30) . After the fibers were placed, Ringers solution was infused at a rate of 2 l/min. We monitored RBC flux to verify that initial hyperemia from insertion trauma had subsided before starting the study protocol. The four MD sites were randomly assigned to receive either 1) Ringers solution (control site), 2) 10 mM N G -nitro-L-arginine methyl ester (L-NAME; Calbiochem, San Diego, CA), to inhibit NOS, 3) 20 mM ascorbic acid (Bioniche Pharma USA, Lake Forest, IL), or 4) 10 mM L-arginine (Sigma). The local heaters were set to 33°C, and baseline RBC flux was recorded for ϳ30 min. After the baseline period, local temperature was increased to 42°C at a rate of 0.5°C every 5 s. Local temperature was then clamped at 42°C for the duration of the local heating protocol. An initial peak in cutaneous blood flow occurs in the first 10 min of heating and is largely due to an axon reflex (30) . Following the nadir, a secondary plateau in cutaneous blood flow occurs after ϳ30 more min of heating and is largely mediated by NO (21, 30) . Once RBC flux reached a stable plateau, around 45 min, the local heaters were set to 43°C, and 28 mM sodium nitroprusside (SNP; Nitropress; Hospira) was infused into all four MD sites to elicit maximal cutaneous vasodilation in each MD site. All pharmacological substances were dissolved in Ringers solution, mixed just prior to use and sterilized using sterile syringe filters (Whatman Puradisc 13 mm Syringe Filters, Florham Park, NJ). L-NAME (10 mM) was chosen because this dose has been shown to sufficiently inhibit nitric oxide synthase in the skin (30) . SNP (28 mM) was chosen because this dose has been shown to elicit maximal vasodilation in the skin (30) . Concentrations greater than 10 mM ascorbic acid or 10 mM L-arginine do not further increase the NO-mediated plateau during local heating in healthy aging (13, 17) . Due to the subject population studied (CKD), we used a higher dose (20 mM) of ascorbic acid.
Blood analyses. Venous blood samples were obtained after a 12-h fast. All samples were collected in tubes containing EDTA and/or sodium heparin. They were immediately centrifuged at 4°C, and plasma was frozen at Ϫ70°C until analysis. Plasma oxidized lowdensity lipoprotein (LDL) was measured using a competitive ELISA (Mercodia, Winston Salem, NC) on EDTA plasma samples. On completion of the assay, absorbance was read at 450 nm on a SpectraMax 340PC microplate reader (Molecular Devices, Sunnydale, CA). Oxidized LDL concentrations are expressed in units per liter. Asymmetric dimethylarginine (ADMA) levels were measured using a competitive ELISA (Alpco Immunoassays, Salem, NH) on sodium heparin plasma samples. On completion of the assay, absorbance was read at 450 nm. ADMA concentrations are expressed in micromoles per liter.
Data analysis. RBC flux data were collected at 40 Hz with a National Instruments PCI-6221 DAQ board and LabView software (National Instruments, Austin, TX). Blood pressure was used to calculate cutaneous vascular conductance (CVC) as RBC flux divided by mean arterial pressure. Baseline and plateau CVC were obtained over a stable 10-min period. Initial peak and nadir CVC were calculated by averaging the highest and lowest values, respectively, over a stable 60-s period. All data are expressed as a percentage of maximal CVC obtained during SNP infusion (%CVC max). A 2 ϫ 4 ANOVA was performed to determine the effect of group, treatment, and group ϫ treatment interaction on %CVCmax. Tukey's post hoc testing was completed to determine between-and within-group differences when appropriate. To assess the contribution of NO to cutaneous vasodilation, we subtracted the plateau %CVC max at the L-NAME site from the plateau %CVCmax at the control site (Ringers) and compared them using an unpaired t-test. We also used unpaired t-tests to compare group demographic information. Alpha level was set at 0.05 for all statistical tests. Data are presented as means Ϯ SE. Post hoc power analysis revealed that we had Ͼ95% power to detect the observed differences the plateau %CVC max between CKD and control groups and between sites within the CKD group.
RESULTS
Subject characteristics. The characteristics of the CKD and healthy control groups can be found in Table 1 . By design, eGFR was 37 Ϯ 5.2 ml·min Ϫ1 ·1.73 m Ϫ2 in the CKD patients. CKD patients had significantly higher blood urea nitrogen and serum creatinine (P Ͻ 0.01). Additionally, the CKD patients had significantly higher systolic blood pressure and mean arterial pressure than controls (P Ͻ 0.05). None of the healthy participants were taking any medications; however, all of the CKD patients were taking antihypertensive medications as well as other medications (see Table 1 ).
Microvascular function. There were no differences in baseline %CVC max between groups or across MD sites [Ringers-CKD: 12 Ϯ 1, healthy controls (HC): 9 Ϯ 1; ascorbic acid (AA)-CKD: 13 Ϯ 3, HC: 12 Ϯ 1; L-Arg-CKD: 11 Ϯ 2, HC: 13 Ϯ 2; L-NAME-CKD: 11 Ϯ 2, HC: 12 Ϯ 1%CVC max ; P Ͼ 0.05]. Absolute maximal CVC was not different between groups across all sites ( Table 2 , P Ͼ 0.05), indicating that the maximal dilatory capacity of the skin vasculature was not different between groups. Figure 1A displays mean %CVC max for the plateau phase of the cutaneous local heating response in the CKD and control subjects. There was a significantly lower plateau %CVC max at the control site (Ringers) in the CKD group compared with HC (76 Ϯ 4 vs. 91 Ϯ 2%CVC max ; P Ͻ 0.05). L-NAME significantly attenuated the plateau in both groups (CKD: 38 Ϯ 4, HC: 40 Ϯ 6%CVC max ). The NO contribution was significantly decreased in the CKD group (CKD: 39 Ϯ 7, HC: 54 Ϯ 5%CVC max ; P Ͻ 0.05). Figure 1B displays the plateau %CVC max at the ascorbic acid and L-arginine sites in both groups. There were no differences in %CVC max between the groups at the two treatment sites (P Ͼ 0.05). The plateau %CVC max in the CKD group was significantly greater at the ascorbic acid and L-arginine sites compared with the Ringers site (AA: 89 Ϯ 2; L-Arg: 90 Ϯ 1; Ringers: 76 Ϯ 4; P Ͻ 0.05; Fig. 2) . Figure 2 displays the initial peak in the cutaneous local heating response in both groups. Initial peak %CVC max was significantly attenuated at the Ringers and L-arginine sites in the CKD group compared with healthy controls (Ringers-CKD: 53 Ϯ 5 vs. HC: 71 Ϯ 4, L-Arg-CKD: 47 Ϯ 4 vs. HC: 68 Ϯ 3%CVC max ; P Ͻ 0.05). However, initial peak %CVC-max did not differ between groups at the ascorbic acid site (CKD: 59 Ϯ 5, HC: 66 Ϯ 5%CVC max ). No difference was observed in initial peak %CVC max between groups at the L-NAME site (P Ͼ 0.05).
Blood analyses. ADMA levels were significantly higher in the CKD group (0.51 Ϯ 0.05 vs. HC: 0.29 Ϯ 0.04 mol/l; P Ͻ 0.01; Fig. 3 ). Oxidized LDL was higher in the CKD group, but did not reach statistical significance (CKD: 61.5 Ϯ 10.2 vs. HC: 44.8 Ϯ 3.5 U/l; P ϭ 0.15; Fig. 3 ).
DISCUSSION
The primary findings of this investigation are 1) the plateau phase of cutaneous vasodilation in response to local heating was impaired in stage 3-4 CKD compared with age-and sex-matched apparently healthy individuals; 2) local infusion of ascorbic acid or L-arginine improved the plateau phase of cutaneous vasodilation in response to local heating in stage 3-4 CKD; and 3) the initial peak in cutaneous vasodilation in response to local heating was also impaired in stages 3-4 CKD Values are means Ϯ SE. n, no of subjects; CKD, chronic kidney disease; BMI, body mass index; ACE, angiotensin converting enzyme; ANG, angiotensin; *P Ͻ 0.05, †P Ͻ 0.01. Values are means Ϯ SE. compared with age-and sex-matched apparently healthy individuals. These findings suggest that oxidative stress and a relative deficit of L-arginine are mechanisms by which microvascular dysfunction occurs in stage 3-4 CKD. Additionally, because the initial peak in response to local heating is largely due to an axon reflex, the lower initial peak observed in the CKD group may represent the onset of neurovascular dysfunction. Our finding of impaired microvascular function in CKD is consistent with previous studies of vascular function in renal disease (3, 11, 32) . Thermally induced cutaneous vasodilation has been found to be reduced in end-stage renal disease patients who were free of CVD and diabetes mellitus (43). Morris et al. (32) reported impaired relaxation responses to acetylcholine in subcutaneous resistance vessels from predialysis and dialysis patients. Forearm blood flow responses to metacholine have been shown to be impaired in moderate renal failure patients (3). Impaired brachial artery flow-mediated dilation has also been reported in stages 3-5 CKD and hemodialysis patients (11) . We found that cutaneous vasodilation in response to local heating was reduced in stage 3-4 CKD, providing further support that microvascular function is impaired early in the progression of CKD. The plateau phase of cutaneous dilation in response to local heating is primarily mediated by NO (21, 30) and endothelial-derived NOS has been shown to be the primary substrate in the forearm skin (22) while others have reported a role for neuronal NOS in the calf skin of postural tachycardia syndrome patients (44) . Our data suggest that the NO contribution to the plateau phase of cutaneous vasodilation in response to local heating is reduced in stage 3-4 CKD.
The impairment in cutaneous vasodilation was improved to the level of the control group by the local infusion of ascorbic acid in the present investigation. Thus it appears that oxidative stress is a mechanism by which microvascular dysfunction occurs in these patients. This finding is consistent with those of previous studies in predialysis renal failure patients, who are more advanced than the stage 3-4 CKD patients that we studied. Cross et al. (8) reported an increase in acetylcholineinduced forearm blood flow with acute administration of ascorbic acid in predialysis renal failure patients. Additionally, oral supplementation of vitamin C improved brachial artery FMD in hemodialysis patients (11) . We studied patients with stage 3-4 CKD, thus our findings indicate that oxidative stress is a mechanism of vascular dysfunction earlier in the progression of kidney disease prior to end stage renal disease and hemodialysis.
It is likely that the local infusion of ascorbic acid improved cutaneous vasodilation in our patients due to a scavenging of superoxide, which can react rapidly with NO, limiting its availability, and result in peroxynitrite formation. Additionally, reactive oxygen species (ROS) promote the oxidation of tetrahydrobiopterin (BH 4 , a critical NOS cofactor), which leads to the uncoupling of eNOS, decreasing NO synthesis and further increasing superoxide production (2) . In addition to directly scavenging ROS, ascorbic acid may have improved cutaneous vasodilation in CKD via stabilization of BH4 by protecting it from oxidation (12), preventing uncoupling of NOS and decreasing superoxide production by NOS.
We also found that local infusion of L-arginine improved cutaneous vasodilation in the CKD group, suggesting that a relative deficit of L-arginine also contributes to endothelial dysfunction in the current patient population. This impairment may be due to increased ADMA levels. ADMA is a naturally occurring amino acid and an endogenous inhibitor of NOS via competition with L-arginine for NOS (49) . Elevated ADMA may lead to increased endothelial NOS uncoupling and decreased NO bioavailability (46) . Thus elevated ADMA may result in a relative deficit of L-arginine and explain our finding of improved cutaneous vasodilation in the presence of L-arginine in the CKD group. Increased ADMA has been shown to be an independent determinant of brachial artery flow-mediated dilation in all stages of CKD (51) and is associated with the prevalence of CVD as well as all-cause and CVD mortality in stage 3-4 CKD (52). It is well documented that ADMA levels are increased in CKD (51) and our data are in agreement. The enzymes involved in the formation of ADMA, PRMTs, as well as DDAH, are redox sensitive (25, 48) . Increases in free radical production, such as superoxide, leads to an increase in PRMT activity and the formation of more ADMA as well as a decrease in DDAH activity and a reduction of ADMA degradation (46) . Thus elevated ADMA and oxidative stress likely have related roles in vascular dysfunction in CKD. A potential common mechanism by which vascular function is impaired in CKD is via uncoupled eNOS. eNOS can be uncoupled by oxidation of BH 4 (10) as well as competitive inhibition by ADMA (42) , thus ascorbic acid and L-arginine may both have improved cutaneous vasodilation in the present study via a recoupling of eNOS. An alternative mechanism for the reduction in L-arginine availability may be due to increased arginase activity. In addition to NO production, L-arginine is used by the endothelium as a substrate in the urea cycle by the enzyme arginase. The two known isoforms of arginase (arginase I and arginase II) exist in the vasculature and have been implicated in endothelial dysfunction (9) . Arginase inhibition has been shown to improve endothelial function in studies of hypertension and aging in both humans and animals (6, 14, 18, 20, 24) . Arginase inhibition has been shown to protect the kidney from structural damage in a rodent model of CKD (5) and arginase inhibition has been suggested as a possible treatment for endothelial dysfunction in CKD. Ascorbic acid has the potential to inhibit arginase activity (37) , which may have occurred in the present study. Future studies are needed in to determine the role of arginase in vascular dysfunction in CKD.
Our finding of an attenuated initial peak in the CKD group compared with healthy controls requires further investigation. The initial increase in skin blood flow in response to local heating is largely due to an axon reflex; however, a portion can be attenuated by NOS antagonism (30, 31) . The attenuated initial peak we observed in CKD was likely mediated by oxidative stress or reduced BH 4 availability since the impairment was improved by the local infusion of ascorbic acid but not L-arginine. Further study is warranted to determine the source of nitric oxide involved in the initial peak but previous work by Kellogg et al. suggests that neither neuronal (23) nor endothelial (22) NOS are involved. Alternatively, ascorbic acid may have other nonspecific effects on the axon reflex that may have resulted in improvement in the CKD group that does not involve nitric oxide.
Interestingly, 4 of 8 CKD patients studied in this investigation were diabetic, although none of them had peripheral neuropathy. A recent investigation by Strom et al. (45) found no difference in the axon-reflex in a group of well controlled type 2 diabetes patients compared with healthy controls (45) . The HbA1c levels (7.05 Ϯ 0.32%) of the CKD patients with diabetes in our study indicate that they were relatively well controlled. Furthermore, our healthy controls and CKD patients without diabetes had similar HbA1c levels (5.43 Ϯ 0.06 and 5.47 Ϯ 0.13%, respectively). There were no differences in the initial peak between CKD patients with and without diabetes (P ϭ 0.48), although we were not adequately powered for this comparison. Thus our data suggest that an early onset of neurovascular dysfunction potentially occurs in CKD, independent of overt symptoms of peripheral neuropathy even if diabetes is well controlled.
A limitation of the current study is that we did not coinfuse L-arginine and ascorbic acid because we are only equipped to assess RBC flux at four sites; therefore we do not know what their combined effect would be. Furthermore, we did not coinfuse L-NAME with L-arginine or ascorbic acid, so we cannot determine whether the improvement in cutaneous vasodilation as a result of either is due to NO or non-NO-dependent mechanisms. An alternative approach to determining the NO contribution in CKD as a result of ascorbic acid and L-arginine would have been to perform a within site infusion of L-NAME following the plateau. Our CKD group was taking antihypertensive and other medications, which have vasoactive effects and may have affected our results. For example, statins have been shown to improve the skin blood flow response to local heating in hypercholesterolemia by inhibiting arginase activity (15) . However, despite taking a variety of medications with vasoactive effects, cutaneous microvascular function was impaired in this cohort of CKD patients.
In summary, we found that cutaneous vasodilation is impaired in stage 3-4 CKD compared with healthy individuals. This impairment was normalized by the local infusion of ascorbic acid or L-arginine in CKD. These findings suggest that oxidative stress and a relative deficit of L-arginine are mechanisms of impaired microvascular function in stage 3-4 CKD and represent possible therapeutic targets to slow renal disease progression and prevent CVD. Chronic antioxidant treatment, combined with L-arginine supplementation, was recently shown to be effective in preventing renal injury and oxidative stress in an animal model of CKD (4) . In addition to antioxidants, BH 4 may offer another therapeutic strategy. BH 4 supplementation, in combination with L-arginine administration, was recently shown to prevent endothelial dysfunction in rats with chronic renal failure (50) . Our data provide mechanistic insight into potential benefits associated with antioxidants/L-arginine and support further study of their therapeutic role in CKD.
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